NASDAQ:AMRSAmyris Stock Price, Forecast & News

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMRS stock has increased by 30.4% and is now trading at $3.86.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amyris.

Amyris is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Amyris.

Amyris Inc (NASDAQ:AMRS) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.56) EPS for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.37.
View Amyris' earnings history.

Shares of Amyris reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $220.6 million.

2 equities research analysts have issued 12-month price targets for Amyris' stock. Their forecasts range from $9.00 to $11.00. On average, they expect Amyris' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 159.1% from the stock's current price.
View analysts' price targets for Amyris.

News coverage about AMRS stock has been trending extremely negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amyris earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Amyris.

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), CVR Energy (CVI), World Fuel Services (INT), Renewable Energy Group (REGI), PBF Energy (PBF), Delek US (DK), Clean Energy Fuels (CLNE), Green Plains (GPRE), REX American Resources (REX), Adams Resources & Energy (AE) and Gevo (GEVO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Advanced Micro Devices (AMD), Canopy Growth (CGC), Intel (INTC), Inovio Pharmaceuticals (INO), Novavax (NVAX), AT&T (T), Bank of America (BAC) and Corbus Pharmaceuticals (CRBP).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.14%), Swiss National Bank (0.11%), Virtus ETF Advisers LLC (0.06%), Principal Financial Group Inc. (0.05%), Essex Investment Management Co. LLC (0.05%) and Edmond DE Rothschild Holding S.A. (0.04%). Company insiders that own Amyris stock include Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang.
View institutional ownership trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, UBS Group AG, Virtus ETF Advisers LLC, and Envestnet Asset Management Inc.. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang.
View insider buying and selling activity for Amyris.

AMRS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Swiss National Bank, Principal Financial Group Inc., Edmond DE Rothschild Holding S.A., ProShare Advisors LLC, SG Americas Securities LLC, New York State Common Retirement Fund, and Davy Global Fund Management Ltd. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr, and Patrick Y Yang.
View insider buying and selling activity for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $3.86.

Amyris has a market capitalization of $629.37 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe.

The official website for Amyris is amyris.com.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]